The 2026Q2 gross margin of 46.9% is a dramatic departure from the 15-23% range observed over the prior eight quarters, suggesting a one-time event or a fundamental change in product mix. Operating margin expanded to 38.1% from 5.3% in the year-ago quarter, but this appears to be amplified by non-recurring gains, as net margin of 22.5% is well above the historical single-digit levels. Investors should monitor whether this margin level is sustainable, as it may be inflated by favorable LCFS/RIN credit pricing or inventory valuation adjustments, which could normalize in subsequent quarters.

The sequential improvement in ROIC from 1.0% in 2026Q1 to 5.3% in 2026Q2 is notable, but the absolute level remains low relative to the capital-intensive nature of the business and the elevated leverage. ROE of 7.6% in 2026Q2, while improved from negative levels in early 2025, still trails the peer average, indicating that the company is not yet generating excess returns on its invested capital. The recent acquisitions (Gelnex, Valley Proteins) have expanded the asset base, and the return on these investments will be a key test of management's capital allocation discipline.

The DIO increase from 39 days in 2026Q1 to 59 days in 2026Q2 suggests a deliberate build-up of inventory, possibly in anticipation of higher input costs or to secure supply, but it also ties up cash. DSO remained stable at 35 days, while DPO rose to 38 days, indicating some supplier leverage, but the overall CCC of 56 days is above the 10-quarter average of approximately 58 days, reflecting ongoing working capital intensity. The efficiency of asset turnover remains low at 0.16, consistent with the heavy fixed-asset base, and any improvement in this metric would signal better utilization of the expanded capacity.

The sequential decline in D/EBITDA from 16.99 in 2026Q1 to 5.30 in 2026Q2 is dramatic, but this is largely due to the spike in EBITDA from the margin surge, not a significant debt reduction. Total debt of $4.2B remains substantial, and interest coverage of 3.37 in 2026Q2, while improved from 0.57 in 2025Q1, is still thin for a company with this leverage. The equity method accounting for DGD may understate true leverage, as DAR's share of JV debt is not on the balance sheet, and investors should monitor the sustainability of the EBITDA improvement to ensure the leverage metrics are not artificially flattered.

The current ratio has improved from 1.38 in 2024Q4, but the quick ratio of 1.02 suggests that inventory is a significant component of current assets, and in a stress scenario, inventory liquidation may be difficult given the specialized nature of the by-products. Cash of $160.7M is modest relative to the $4.2B debt load, and the company's ability to service debt in a downturn would rely heavily on operating cash flow, which has been volatile. The recent FCF generation of $404.6M in 2026Q2 is encouraging, but investors should assess whether this is sustainable or a result of favorable working capital timing.